CN101176731B - 积雪草酸在抗肺纤维化方面的应用 - Google Patents
积雪草酸在抗肺纤维化方面的应用 Download PDFInfo
- Publication number
- CN101176731B CN101176731B CN2006101180416A CN200610118041A CN101176731B CN 101176731 B CN101176731 B CN 101176731B CN 2006101180416 A CN2006101180416 A CN 2006101180416A CN 200610118041 A CN200610118041 A CN 200610118041A CN 101176731 B CN101176731 B CN 101176731B
- Authority
- CN
- China
- Prior art keywords
- group
- asiatic acid
- pulmonary fibrosis
- acid powder
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 title claims abstract description 57
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 title claims abstract description 57
- 229940011658 asiatic acid Drugs 0.000 title claims abstract description 57
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 241000700159 Rattus Species 0.000 claims description 34
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 6
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000002285 radioactive effect Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 description 41
- 210000004072 lung Anatomy 0.000 description 29
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 24
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 16
- 229960003957 dexamethasone Drugs 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 102000002734 Collagen Type VI Human genes 0.000 description 8
- 108010043741 Collagen Type VI Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101800004490 Endothelin-1 Proteins 0.000 description 5
- 102100033902 Endothelin-1 Human genes 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000002601 radiography Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010001889 Alveolitis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000037273 Pathologic Processes Diseases 0.000 description 3
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 3
- 206010067953 Radiation fibrosis Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004276 hyalin Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000009054 pathological process Effects 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 201000000258 compensatory emphysema Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 2
- 229960002060 secobarbital Drugs 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 101000925461 Rattus norvegicus Endothelin-1 Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OOTXFYSZXCPMPG-BMYLZFHVSA-N ursane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5[C@H]4CC[C@@H]3[C@]21C OOTXFYSZXCPMPG-BMYLZFHVSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101180416A CN101176731B (zh) | 2006-11-08 | 2006-11-08 | 积雪草酸在抗肺纤维化方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101180416A CN101176731B (zh) | 2006-11-08 | 2006-11-08 | 积雪草酸在抗肺纤维化方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101176731A CN101176731A (zh) | 2008-05-14 |
CN101176731B true CN101176731B (zh) | 2010-08-11 |
Family
ID=39403252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101180416A Expired - Fee Related CN101176731B (zh) | 2006-11-08 | 2006-11-08 | 积雪草酸在抗肺纤维化方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101176731B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755329B (zh) * | 2011-04-29 | 2016-03-09 | 上海医药工业研究院 | 积雪草酸盐气雾剂及其制备方法 |
CN102755330B (zh) * | 2011-04-29 | 2015-06-24 | 上海医药工业研究院 | 积雪草酸盐颗粒剂及其制备方法 |
CN104736151B (zh) * | 2012-10-26 | 2019-04-23 | 香港中文大学 | 纤维化的柚皮素和积雪草酸组合治疗 |
CN104147015B (zh) * | 2014-06-27 | 2016-05-25 | 孙蕾 | 闭花木酮Cleistanone的二乙胺衍生物在制备抗慢性阻塞性肺病药物中的应用 |
CN112402471A (zh) * | 2019-08-21 | 2021-02-26 | 盈科瑞(横琴)药物研究院有限公司 | 一种积雪草总酸的制备方法及其制备的积雪草总酸和应用 |
-
2006
- 2006-11-08 CN CN2006101180416A patent/CN101176731B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Mi-Sook Dong, et al.Structure-Related Cytotoxicity and Anti-Hepatofibric EffectofAsiatic Acid Derivatives in Rat Hepatic Stellate Cell-Line,HSC-T6.Arch Pharm Res27 5.2004,27(5),512-517. |
Mi-Sook Dong, et al.Structure-Related Cytotoxicity and Anti-Hepatofibric EffectofAsiatic Acid Derivatives in Rat Hepatic Stellate Cell-Line,HSC-T6.Arch Pharm Res27 5.2004,27(5),512-517. * |
李才等.器官纤维化--基础与临床 1.人民卫生出版社,2003,1-2,8. |
李才等.器官纤维化—基础与临床 1.人民卫生出版社,2003,1-2,8. * |
Also Published As
Publication number | Publication date |
---|---|
CN101176731A (zh) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101919870B (zh) | 甘草次酸、甘草酸在制备预防或治疗肺纤维化药物中的应用 | |
CN101176731B (zh) | 积雪草酸在抗肺纤维化方面的应用 | |
AU2016390488B9 (en) | Application of dimethylamino micheliolide | |
US20220332796A1 (en) | Fused polypeptide with multifunctional activities and use thereof | |
CN1439376A (zh) | 一种抗肺肝纤维化的积雪草苷中药制剂 | |
CN102813662A (zh) | 一种甘草次酸-30-酰胺类衍生物的新用途 | |
CN101164545A (zh) | 积雪草苷在抗肺纤维化方面的新应用 | |
CN101543574B (zh) | 一种治疗肺间质纤维化的中药组合物 | |
CN103285022A (zh) | 用于制备治疗多囊卵巢综合征的中药单体组合物及其制备方法 | |
CN105998821A (zh) | 防治阴虚肺热型放射性肺损伤的中药制剂及其制备方法 | |
CN101108262B (zh) | 一种肿瘤介入栓塞剂去甲斑蝥素-海藻酸钙/聚乳酸-乙醇酸共聚物控释微球 | |
Qu et al. | Induction of substantial myocardial regeneration by an active fraction of the Chinese herb Rosa laevigata Michx | |
CN115414341B (zh) | 一种包含α-紫罗兰酮用于抗紫外线暴露引起肾脏损伤的组合物 | |
CN116236513B (zh) | 黑沙蒿根提取物在制备抗类风湿关节炎药物中的应用 | |
CN117797163A (zh) | 一种用于防治肺部疾病的组合物 | |
Lu et al. | Yangonin treats inflammatory osteoporosis by inhibiting the secretion of inflammatory factors and RANKL expression | |
CN100346808C (zh) | 治疗老年性痴呆的药物以及相关中药组合物的应用 | |
CN117159518A (zh) | 一种大黄素在制备预防或治疗动脉粥样硬化药物组合物中的应用 | |
CN114767820A (zh) | 一种治疗心脏外科术后全身炎症反应的中药药物组方 | |
CN1148182C (zh) | 茶多酚在制备抑制β-淀粉样蛋白聚集和纤维形成的药物中的应用 | |
CN113230340A (zh) | 补肾防喘方在制备治疗肺纤维化的药物中的应用 | |
Zhang et al. | Synergistic amelioration between Ligusticum striatum DC and borneol against cerebral ischemia by promoting astrocytes–mediated neurogenesis | |
WO2016049811A1 (zh) | 一种富含三萜的抗肿瘤组合物及其制备方法 | |
CN104013737A (zh) | 一种用于治疗放射性肺损伤的药物组合物及其制备方法 | |
CN101244072B (zh) | 积雪草苷在制备抗肺纤维化迁延期的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG HONGDOUSHAN PHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111111 Address after: 200040 Beijing West Road, Shanghai, No. 1320 Co-patentee after: Heilongjiang Hongdoushan Pharmaceutical Co., Ltd. Patentee after: Shanghai Institute of pharmaceutical industry Address before: 200040 Beijing West Road, Shanghai, No. 1320 Patentee before: Shanghai Institute of pharmaceutical industry |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: HEILONGJIANG HONGDOUSHAN PHARMACEUTICAL CO., LTD. Effective date: 20150507 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150507 Address after: 200040 Beijing West Road, Shanghai, No. 1320 Patentee after: Shanghai Institute of pharmaceutical industry Address before: 200040 Beijing West Road, Shanghai, No. 1320 Patentee before: Shanghai Institute of pharmaceutical industry Patentee before: Heilongjiang Hongdoushan Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20181108 |
|
CF01 | Termination of patent right due to non-payment of annual fee |